PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Clinical Pharmacy, School of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.\', \'Education Development Center, Mazandaran University of Medical Sciences, Sari, Iran.\', \'Antimicrobial Resistance Research Center, Mazandaran University of Medical Sciences, Sari, Iran.\', \'Gastrointestinal Cancer Research Center, Cancer Research Institute, Mazandaran University of Medical Sciences, Sari, Iran.\', \'Pharmaceutical Sciences Research Center, Hemoglobinopathy Research Institute, Mazandaran University of Medical Sciences, Sari, Iran.\', \'Liver and Pancreatobiliary Diseases Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran.\', \'School of Public Health, Imperial College London, London, UK.\', \'Cardiff and Vale University Health Board, Cardiff, UK.\', \'Accident and Emergency Department, Homerton University Hospital NHS Trust, London, UK.\', \'Department of Infectious Disease, Imperial College London, London, UK.\', \'Department of Translational Medicine, University of Liverpool, UK.\', \'Gut and Liver Research Center, Mazandaran University of Medical Sciences, Sari, Iran.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1093/jac/dkaa332
?:doi
?:hasPublicationType
?:journal
  • The Journal of antimicrobial chemotherapy
is ?:pmid of
?:pmid
?:pmid
  • 32812025
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
?:title
  • Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial.
?:type
?:year
  • 2020

Metadata

Anon_0  
expand all